Osborne Clarke has advised iOnctura B.V., a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, on its EUR80 million Series B financing. The funding round was led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council (EIC), as well as existing investors M Ventures, Inkef Capital, VI Partners, Schroders Capital and 3B Future Health Fund.
Osborne Clarke also had the pleasure to assist iOnctura on its Series A financing round.
The Osborne Clarke core deal team consisted of Partner Herke van Hulst, Senior Associate Wouter Kok and Associate Angela Saldanha and further included partner/ civil-law notary Cars-Jan van Gool, Associate Femke Izendoorn and Tax partner Job van der Pol.
Corporate communications and press contacts
Connect with one of our experts
![](https://oc-static.poweredbyproctors.co.uk/public/images/23/11/30/2%20Herke.vanHulst.png?VersionId=RywvMTKC0R_AxZEBM1IrXJi84icF2m89)
![](https://oc-static.poweredbyproctors.co.uk/public/lawyer_images/wouter.kok.png?VersionId=OILj9aix9_jrAvrgQ3zRmgzkC1N1lUcJ)
![](https://oc-static.poweredbyproctors.co.uk/public/lawyer_images/angela.saldanha.png?VersionId=hHp.YAIJTilPhbJfTrPlpiJJtI_kDzsc)
![](https://oc-static.poweredbyproctors.co.uk/public/lawyer_images/carsjan.vangool.png?VersionId=MSr0c2FVXJq2THbv07sqgZ5JrYSA.ijc)
![](https://oc-static.poweredbyproctors.co.uk/public/images/23/08/07/femke.izendoorn.png?VersionId=6UyWRzeVQVH6jxIVzvb6v0nn9Ks5iB.8)
![](https://oc-static.poweredbyproctors.co.uk/public/lawyer_images/job.vanderpol.png?VersionId=bn_L3VKBtOx6jDMHXRc0853t4BUQO8s.)